We serve Z-ALA-ALA-OME CAS:2483-51-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Z-ALA-ALA-OME
CAS.NO: 2483-51-4
Molecular Formula: C15H20N2O5
Molecular Weight: 308.33000
Synonyms:
Z-L-Ala-L-Ala-OMe
Z-L-ALANYL-L-ALANINE METHYL ESTER
Z-Ala-Ala-OCH3
Cbz-Ala-Ala-OMe
Physical and Chemical Properties:
Density:/
Boiling point:/
Melting point: 93-94 °C
Flash point:/
Refractive index: /
Specification:
Appearance: White powder
Purity:≥98%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:-15ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.
Contact us for information like Z-ALA-ALA-OME chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cbz-Ala-Ala-OMe physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Z-L-ALANYL-L-ALANINE METHYL ESTER Use and application,Z-L-Ala-L-Ala-OMe technical grade,usp/ep/jp grade.
Related News: The upstream of pharmaceutical intermediates is the basic chemical raw material industry. Basic chemical raw materials are bulk commodities and prices fluctuate greatly, which directly affects the production costs of enterprises.2-Chloro-4-isocyanato-1-methylbenzene manufacturer The upstream of pharmaceutical intermediates is the basic chemical raw material industry. Basic chemical raw materials are bulk commodities and prices fluctuate greatly, which directly affects the production costs of enterprises.2-Fluoro-4-methyaniline supplier TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.1-(2-Iodoethyl)-4-octylbenzene vendor TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.
